Breast Cancer Drug - Trastuzumab Emtansine - Mechanism of Action

Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metas...Подробнее

antibody drug conjugateПодробнее

【HER2 inhibitors】Trastuzumab(Herceptin®), Pertuzumab, Lapatinib, Antibody-drug conjugates (KADCYLA®)Подробнее

Dr. Hong's Biotechnology Lecture 04: Cancers and Antibody Drug ConjugateПодробнее

Dr Shaheenah Dawood HER 2 positiveПодробнее

Breast Cancer Update - 4th MarchПодробнее

Antibody Drug Conjugates: The end of chemotherapy | 2023 West Oncology ConferenceПодробнее

#Trastuzumab | Uses, Dosage, Side Effects and Mechanism | HerceptinПодробнее

Pharmacology of SACT (Part 2)Подробнее

ALK Positive Lung Cancer in 2023 and Beyond: Thinking Outside the Box with Dr. Alice ShawПодробнее

2022 KU Post San Antonio Review | Metastatic HER2 Positive Breast Cancer: Novel Treatment ApproachesПодробнее

Antibody-Drug Conjugates Mechanism of ActionПодробнее

Trastuzumab Deruxtecan for Breast Cancer | NEJMПодробнее

HER2 Positive Breast Cancer: What's New in Treatment and Research at MBC Patient Forum 2019Подробнее

Adjuvant treatment in Her2+ve EBCПодробнее

Aequilibrium Pharma Anti HER2 Mechanisms of Approved mAbs HER2 Inhibitors Trastuzumab+PertuzumabПодробнее

Breast Cancer Drug - Trastuzumab EmtansineПодробнее

Antibody drug conjugates in lung cancerПодробнее

Focus on the mode of action of naratuximab emtansineПодробнее